Analytical Data
-
Gene name
ARID4B
- Application
-
Alternative Names
180 kDa Sin3-associated polypeptide (Sin3-associated polypeptide p180) (Breast cancer-associated antigen BRCAA1) (Histone deacetylase complex subunit SAP180) (Retinoblastoma-binding protein 1-like 1) (ARID domain-containing protein 4B) (BRCAA1) (RBBP1L1) (RBP1L1) (SAP180)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q4LE39
-
Expression Region
167-415aa
-
Molecular Weight
32.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ARID4B (AT-rich interactive domain-containing protein 4B) is a member of the ARID family of proteins, which are implicated in various biological processes, including gene regulation, chromatin remodeling, and development. Research on ARID4B has gained attention due to its potential role in cancer biology, particularly in promoting tumor growth and metastasis. Studies have shown that ARID4B is often overexpressed in several cancer types, including breast cancer and leukemia, suggesting its involvement in oncogenic pathways. Additionally, ARID4B has been found to interact with key transcription factors and chromatin modifiers, indicating its role in modulating gene expression. Understanding the functional dynamics of ARID4B, particularly its reorganization and interactions within cellular contexts, is critical for elucidating its contributions to tumorigenesis. Investigating ARID4B's mechanism of action at both molecular and cellular levels could provide insights into novel therapeutic targets, enhancing the effectiveness of cancer treatments. Thus, the study of ARID4B and its recombinant proteins serves not only to unravel fundamental biological processes but also to pave the way for innovative strategies in cancer therapy.
